|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2016. Cancer J Clinical. 66:7–30. 2016. View Article : Google Scholar
|
|
2
|
Che AJ, Zhang JY, Li CH, Chen XF, Hu ZD
and Chen XG: Separation and determination of active components in
Radix Salviae miltiorrhizae and its medicinal preparations by
nonaqueous capillary electrophoresis. J Sep Sci. 27:569–575. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou L, Zuo Z and Chow MS: Danshen: An
overview of its chemistry, pharmacology, pharmacokinetics, and
clinical use. J Clin Pharmacol. 45:1345–1359. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yuen JS and Macaulay VM: Targeting the
type 1 insulin-like growth factor receptor as a treatment for
cancer. Expert Opin Ther Targets. 12:589–603. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chitnis MM, Yuea JS, Protheroe AS, Pollak
M and Macaulay VM: The type 1 insulin-like growth factor receptor
pathway. Clin Cancer Res. 14:6364–6370. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Santarpia L, Lippman SM and El-Naggar AK:
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.
Expert Opin Ther Targets. 16:103–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
McCubrey JA, Steelman LS, Kempf CR,
Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra
M, Basecke J, et al: Therapeutic resistance resulting from
mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
J Cell Physiol. 226:2762–2781. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang CY, Chiu TL, Kuo SJ, Chien SY, Chen
DR and Su CC: Tanshinone IIA inhibits the growth of pancreatic
cancer BxPC-3 cells by decreasing protein expression of TCTP, MCL-1
and Bcl-xL. Mol Med Rep. 7:1045–1049. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Su CC: Tanshinone IIA could inhibit
pancreatic cancer BxPC-3 cells through increasing PERK, ATF6,
caspase-12 and CHOP expression to induce apoptosis. J Biomedical
Sci Engineering. 8:149–159. 2015. View Article : Google Scholar
|
|
12
|
Fronza M, Murillo R, Ślusarczyk S, Adams
M, Hamburger M, Heinzmann B, Laufer S and Merfort I: In vitro
cytotoxic activity of abietane diterpenes from Peltodon
longipes as well as Salvia miltiorrhiza and Salvia
sahendica. Bioorg Med Chem. 19:4876–4881. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kranenburgm O, Gebbink MF and Voest EE:
Stimulation of angiogenesis by Ras proteins. Biochim Biophys Acta.
1654:23–37. 2004.PubMed/NCBI
|
|
14
|
Boonstra J, Rijken P, Humbel B, Cremers F,
Verkleij A and van Bergen en Henegouwen P: The epidermal growth
factor. Cell Biol Int. 19:413–430. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cary LA, Han DC and Guan JL:
Integrin-mediated signal transduction pathways. Histol Histopathol.
14:1001–1009. 1999.PubMed/NCBI
|
|
16
|
Stacey DW: Cyclin D1 serves as a cell
cycle regulatory switch in actively proliferating cells. Curr Opin
Cell Biol. 15:158–163. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vandamme T, Beyens M, de Beeck KO, Dogan
F, van Koetsveld PM, Pauwels P, Mortier G, Vangestel C, de Herder
W, Van Camp G, et al: Long-term acquired everolimus resistance in
pancreatic neuroendocrine tumours can be overcome with novel
PI3K-AKT-mTOR inhibitors. Br J Cancer. 114:650–658. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Franklin RA, Montalto G, Cervello M, Nicoletti F, Fagone
P, Malaponte G, et al: Mutations and deregulation of
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy
response. Oncotarget. 3:954–987. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sebolt-Leopold JS: Advances in the
development of cancer therapeutics directed against the
Ras-mitogen-activated protein kinase pathway. Clin Cancer Res.
14:3651–3656. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Haura EB, Ricart AD, Larson TG, Stella PJ,
Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner
KD, et al: A phase II study of PD-0325901, an oral MEK inhibitor,
in previously treated patients with advanced non-small cell lung
cancer. Clin Cancer Res. 16:2450–2457. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Quah SY, Tan MS, Teh YH and Stanslas J:
Pharmacological modulation of oncogenic Ras by natural products and
their derivatives: Renewed hope in the discovery of novel anti-Ras
drugs. Pharmacol Ther. 162:35–57. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Goodman MD and Saif MW: Adjuvant therapy
for pancreatic cancer. JOP. 15:87–90. 2014.PubMed/NCBI
|
